Mingtao Zeng

Associate Professor of the Center of Emphasis in Infectious Diseases. We are developing new-generation vaccines against human respiratory pathogens such as influenza viruses, Streptococcus pneumoniae, nontypeable Haemophilus influenzae (NTHi), and agents important for biodefense such as Bacillus anthracis, botulinum neurotoxins, and Francisella tularensis. Our multi-component candidate vaccines are being formulated and delivered by noninvasive nasal, oral, or transcutaneous manners, using recombinant viruses, bacteria, plasmid DNA, and detoxified bacterial toxins as vaccine antigen delivery vehicles. The noninvasive and easy administration procedures are expected to eliminate pain associated with needle injection, to reduce the requirement for specially trained personnel and equipment, and to permit rapid vaccine deployment in a short time frame at a low cost.

External Link (elpaso.ttuhsc.edu)